RCEP: India in a Catch-22

By Chaitanya Netkalappa, Deccan Herald

The Regional Comprehensive Economic Partnership (RCEP) is a proposed Free Trade Agreement between the Asean countries and six other member countries that aims to boost goods and services trade by eliminating most tariff and non-tariff barriers – a move that, in theory, would provide India’s consumers greater choice of quality products at affordable rates as well as boost service (and goods) exports from the nation’s producers. Continue reading

Posted in IPR, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

Humira’s Best-Selling Drug Formula: Start at a High Price. Go Higher.

Humira is the best-selling prescription drug in the world. You may have seen the commercials.

Because of Humira, a woman with rheumatoid arthritis can wash her puppy in the bathtub, another with colitis can stroll happily through a fair packed with food vendors, while a third suffering from psoriasis can go to the gym without hiding her neck.

But they probably wouldn’t all look so relieved if they saw the bill. The price of Humira, an anti-inflammatory drug dispensed in an injectable pen, has risen from about $19,000 a year in 2012, to more than $38,000 today, per patient, after rebates, according to SSR Health, a research firm. That’s an increase of 100 percent. Continue reading

Posted in Biologics/Biosimilars, Drug prices, Uncategorized | Leave a comment

Cancer Drug Price Rises 1, 400% With No Generic to Challenge It

By Peter Loftus, Wall Street Journal

Since 2013, the price of a 40-year-old, off-patent cancer drug in the U.S. has risen 1,400%, putting the life-extending medicine out of reach for some patients.

Introduced in 1976 to treat brain tumors and Hodgkin lymphoma, lomustine has no generic competition, giving seller NextSource Biotechnology LLC significant pricing power.

The U.S. Food and Drug Administration is seeking to encourage more competition for drugs like lomustine, one of at least 319 drugs for which U.S. patents have expired but which have no generic copies, according to a list the agency published earlier this month. Continue reading

Posted in Cancer, Drug prices, Generics, Price hikes, Uncategorized | Leave a comment

UACT statement regarding Chilean Congress resolution calling on the President to advance the compulsory licensing request on HCV drugs

January 8, 2018 New Delhi

Source: U Act

UACT applauds the Chilean Congress resolution calling on the President to advance the compulsory licensing request on HCV drugs made in March 2017 by patients, advocates including Innovarte NGO, and elected officials. The resolution, Number 1014, passed by a 96-0 vote with one abstention, and includes the signatures of representatives across the entire political spectrum 1.

In Chile, the private market price of sofosbuvir at the time of the compulsory licensing request was approximately $36,000 USD per patient. This price is well in excess of Chile’s GNI per capita of $14,100 USD 2. The Ministry of Health currently pays $7,000 USD for a three-month supply of sofosbuvir, but is unable to treat many of the thousands of patients that require treatment, thus forcing patients to either pay exorbitant and often unaffordable prices or go untreated.

Continue reading

Posted in Compulsory Licensing, Hepatitis C | Leave a comment

Justice Prabha Sridevan on Life, Laughter and IP

By Shamnad Basheer, Spicy IP | January 4, 2018

photoAs promised in our new year post on the relativity of “newness” (and the impending death of the patent system), we bring to you our freshly minted SpicyIP Interview series. And who better to kick this off than the inimitable Justice Prabha Sridevan.

She hardly needs an introduction, as her legacy is stamped indelibly on many a fine Indian IP decision (which she penned both as high court judge and later, as the Chairman of the Intellectual Property Appellate Tribunal[IPAB]).  Continue reading

Posted in Compulsory Licensing, Patent, Uncategorized | Leave a comment

Wrapping Up 2017 – some noteworthy medicines law and policy events.

2017 was a significant year for access to medicines and other medicines policy related events. Here are a few highlights of the last 12 months.

January 2017 kicked off with the publication of the report by the Lancet Commission on Essential Medicines Policies in The Lancet.  The commission reported that providing access to a basic package of 201 essential medicines (378 dosage forms) in all low and middle-income countries cost between US$ 77.4 and US$ 151.9 billion (or US$ 13 to US$ 25 per capita). The large majority of low-income countries and 13 out 47 middle-income countries, spent less than US$ 13 per capita on pharmaceuticals, indicating the need for careful selection and increased spending. To put these figures in context: the 2017 world pharmaceutical market was valued at around US$ 1.2 trillion. The Lancet Commission also recommended the use of delinkage-based models to finance the development of new affordable essential medicines. Continue reading

Posted in Compulsory Licensing, Data Exclusivity, ISDS, TRIPS, Uncategorized | Leave a comment

Formal Submission -The National Viral Hepatitis Action Plan(2017–20)

22nd Dec, New Delhi

Formal Submission -The National Viral Hepatitis Action Plan(2017–20) Technical inputs to address viral hepatitis in key vulnerable populations

People living with HIV/HCV co-infection, Men who have Sex with Men (MSM), transgenders (TGs), People who Inject Drugs (PWIDs), sex workers, people living with HCV (Hepatitis C Virus), who are all disproportionately affected by viral hepatitis, welcomed the Government of India’s initiative to launch a national programme on viral hepatitis to help reduce the burden of chronic liver disease, cancer, and death in the country and made a submission on strategies to improve the national response to viral hepatitis with a focus on HBV and HCV. 

Submission can be read here.


Posted in Hepatitis C, Right to Health | Leave a comment